title: A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.
abstract: Previous research in this laboratory concerning delta9-tetrahydrocannabinol-induced spinal antinociception indicated the critical role of dynorphin A-(1-17) in spinal antinociception following acute intrathecal (i.t.) administration. In the present study, tolerance development to delta9-tetrahydrocannabinol-induced spinal antinociception attenuated delta9-tetrahydrocannabinol-induced modulation of immunoreactive dynorphin A-(1-17). These data indicate that at lower doses of drug, desensitization of the cannabinoid receptor inhibits stimulation of downstream dynorphinergic neurons. However, at higher doses of drug, desensitization is overcome and spinal dynorphin A concentrations are increased by delta9-tetrahydrocannabinol. Antinociception in the absence of elevated dynorphin A-(1-17) levels in the tolerant rat suggests that factors other than the attenuated dynorphin release are components of antinociception in the tolerant state. The shift from the critical role of dynorphin A in cannabinoid antinociception vs. that in the non-tolerant state may indicate tolerance also at the kappa-opioid receptor, a role as yet undetermined.
authors.affiliation: Department of Pharmacology and Toxicology, Virginia Commonwealth University/Medical College of Virginia, Richmond 23298-0613, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Mason
authors.forename: J
authors.initials: J
authors.lastname: Lowe
authors.forename: S P
authors.initials: SP
authors.lastname: Welch
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000008:administration & dosage / Q000494:pharmacology*; D004361:Drug Tolerance; D004399:Dynorphins / Q000134:cerebrospinal fluid / Q000378:metabolism*; D007278:Injections, Spinal; D008297:Male; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D017473:Receptors, Opioid, kappa / Q000187:drug effects; D013373:Substance P / Q000378:metabolism
chemical_list: D000700:Analgesics; D017473:Receptors, Opioid, kappa; D013373:Substance P; D004399:Dynorphins; D013759:Dronabinol